Stock ONCOLOGY VENTURE A/S
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. Oncology Venture A/S Nasdaq Stockholm

Equities

End-of-day quote Nasdaq Stockholm
Other stock markets
- SEK - Intraday chart for Oncology Venture A/S
06-25 Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer CI
05-24 Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial CI

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Ladenburg Thalmann Downgrades Allarity Therapeutics to Neutral From Buy
MT
Ladenburg Thalmann Initiates Allarity Therapeutics at Buy with $8 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLR Stock
  4. Stock
  5. News Oncology Venture A/S
  6. Analyst Reco.